Scientist - Delivery Sciences - Targeted LNPs
NewLimit
Scientist - Delivery Sciences - Targeted LNPs
NewLimit
Develops epigenetic medicines to extend healthspan
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat aging by reprogramming the epigenome, a new therapeutic mechanism to restore youthful function in aged cells. We’ve built the world’s leading experimental and artificial intelligence system to discover reprogramming medicines at massive scale. Our first products are focused on restoring youthful metabolic, endothelial, and immune function.
NewLimit is seeking a Scientist to design, formulate and characterize targeted LNPs (tLNPs) with antibody conjugates, Nanobodies, and scFv’s to build our targeting LNP platform with a particular focus on getting nucleic acid payloads into target cells and tissues beyond the liver.
This is a hands-on bench role with targeting compositional and reaction design ownership. You will work closely with the Delivery Sciences and biology teams to design and build relevant targeting lipids portfolio for New Limit’s pipeline programs.
NewLimit provides generous benefits so our team can remain focused on our mission:
Salary Range: $130,000 to $171,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.
NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.
Explore more opportunities at NewLimit